首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives
【24h】

Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives

机译:用于治疗阿尔茨海默氏病的双重功能胆碱酯酶和MAO抑制剂:同异黄酮衍生物的合成,药理学分析和分子模型

获取原文
获取原文并翻译 | 示例
           

摘要

Because of the complexity of Alzheimer's disease (AD), the multi-target-directed ligand (MTDL) strategy is expected to provide superior effects for the treatment of AD, instead of the classic one-drug-one-target strategy. In this context, we focused on the design, synthesis and evaluation of homoisoflavonoid derivatives as dual acetyl cholinesterase (AChE) and monoamine oxidase (MAO-B) inhibitors. Among all the synthesized compounds, compound 10 provided a desired balance of AChE and hMAO-B inhibition activities, with IC50 value of 3.94 and 3.44M, respectively. Further studies revealed that compound 10 was a mixed-type inhibitor of AChE and an irreversible inhibitor of hMAO-B, which was also confirmed by molecular modeling studies. Taken together, the data indicated that 10 was a promising dual functional agent for the treatment of AD.
机译:由于阿尔茨海默氏病(AD)的复杂性,多靶标定向配体(MTDL)策略有望为AD的治疗提供更好的效果,而不是经典的“一药一靶”策略。在这种情况下,我们专注于设计,合成和评估作为双乙酰胆碱酯酶(AChE)和单胺氧化酶(MAO-B)抑制剂的均异黄酮衍生物。在所有合成的化合物中,化合物10提供了所需的AChE和hMAO-B抑制活性平衡,IC50值分别为3.94和3.44M。进一步的研究表明,化合物10是AChE的混合型抑制剂和hMAO-B的不可逆抑制剂,这也得到了分子模型研究的证实。两者合计,数据表明10是一种有前途的双功能药物治疗AD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号